文献速递肥胖与代谢综合征

早孕期血浆全氟及多氟烷基物质(PFAS)与母亲中年肥胖度

Early Pregnancy Plasma Per- and Polyfluoroalkyl Substances (PFAS) and Maternal Midlife Adiposity.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

在547名Project Viva参与者中,早孕期(平均孕10.0周)血浆6种PFAS浓度与中年肥胖指标(平均随访17.7年)的关联分析显示,全氟辛烷磺酸(PFOS)每翻倍与中年体重增加3.8 kg(95%CI:1.6,5.9)相关,BKMR分析中PFOS与体重、躯干脂肪量、全身脂肪量正相关,而全氟壬酸和全氟己烷磺酸呈负相关,整体PFAS混合物未见关联。

要点

  • 早孕期PFOS每翻倍与中年体重增加3.8 kg(95%CI:1.6,5.9)相关。
  • BKMR分析中PFOS与中年体重正相关(7.7 kg,95%CI:4.0,11.5)。
  • 全氟壬酸与中年体重负相关(-6.0 kg,95%CI:-8.5,-3.5)。

核心结论

  • 部分早孕期PFAS可能对母亲中年肥胖度产生不同影响,进而影响晚年母亲心血管代谢健康。

研究设计与样本

  • 研究纳入547名Project Viva参与者,早孕期平均孕10.0周、平均年龄32.5岁,检测血浆6种PFAS浓度,中年肥胖结局平均随访17.7年、平均年龄50.7岁,包括体重、腰围、躯干脂肪量和全身脂肪量,采用线性回归和贝叶斯核机器回归(BKMR)分析。

主要发现

  • 线性回归估计全氟辛烷磺酸(PFOS)每翻倍与中年体重增加3.8 kg(95%CI:1.6,5.9)相关,2-(N-乙基-全氟辛烷磺酰胺基)乙酸酯每翻倍与体重增加2.3 kg(95%CI:0.9,3.7)相关。
  • BKMR分析比较第75百分位与第25百分位浓度,PFOS与中年体重增加7.7 kg(95%CI:4.0,11.5)、躯干脂肪量增加1.2 kg(95%CI:0.0,2.3)、全身脂肪量增加3.0 kg(95%CI:0.8,5.2)正相关。
  • BKMR分析中全氟壬酸与中年体重降低6.0 kg(95%CI:-8.5,-3.5)、腰围降低1.8 cm(95%CI:-3.2,-0.3)、躯干脂肪量降低0.8 kg(95%CI:-1.5,-0.1)、全身脂肪量降低1.4 kg(95%CI:-2.7,-0.3)相关。
  • BKMR分析中全氟己烷磺酸与躯干脂肪量降低0.8 kg(95%CI:-1.5,-0.1)、全身脂肪量降低1.4 kg(95%CI:-2.6,-0.2)相关。
  • 整体PFAS混合物与中年肥胖指标未见关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Evidence suggests that exposure to per- and polyfluoroalkyl substances (PFAS) increases the risk of developing cardiometabolic disease risk factors. Limited research has evaluated associations between PFAS, assessed during pregnancy, a sensitive window for maternal endocrine effects, and long-term maternal adiposity. OBJECTIVE: Estimate associations of early pregnancy measures of individual PFAS, and PFAS mixtures, with maternal adiposity in midlife. METHODS: We studied 547 Project Viva participants with measures of early pregnancy (mean gestation 10.0 weeks; mean age 32.5 years) plasma concentrations of 6 PFAS and midlife adiposity outcomes (mean follow-up 17.7 years; mean age 50.7 years), including weight, waist circumference (WC), trunk fat mass (TFM), and total body fat mass (TBFM). We used linear regression and Bayesian Kernel Machine Regression (BKMR). RESULTS: Linear regression estimated higher midlife weight per doubling of perfluorooctane sulfonate (PFOS) (3.8 kg [95% CI: 1.6, 5.9]) and 2-(N-ethyl-perfluorooctane sulfonamido) acetate (2.3 kg [95% CI: 0.9, 3.7]). BKMR analyses of single PFAS plasma concentrations (comparing the 25th percentile concentration to the 75th percentile) showed a positive association between PFOS and midlife adiposity (weight: 7.7 kg [95% CI: 4.0, 11.5]; TFM: 1.2 kg [95% CI: 0.0, 2.3]; TBFM: 3.0 kg [95% CI: 0.8, 5.2]), but inverse associations with perfluorononanoate (weight: -6.0 kg [95% CI: -8.5, -3.5]; WC: -1.8 cm [95% CI: -3.2, -0.3]; TFM: -0.8 kg [95% CI: -1.5, -0.1]; TBFM: -1.4 kg [95% CI: -2.7, -0.3]) and perfluorohexane sulfonate (TFM: -0.8 kg [95% CI: -1.5, -0.1]; TBFM: -1.4 kg [95% CI: -2.6, -0.2]). No associations were observed with the overall PFAS mixture. CONCLUSION: Select PFAS, assessed in pregnancy, may differentially affect maternal midlife adiposity, influencing later-life maternal cardiometabolic health.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Burdeau JA, Stephenson BJK, Chavarro JE, et al. Early Pregnancy Plasma Per- and Polyfluoroalkyl Substances (PFAS) and Maternal Midlife Adiposity. J Clin Endocrinol Metab. 2025. PMID: 39235224. doi:10.1210/clinem/dgae542

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。